BACK (IMAC Holdings) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is IMAC Holdings Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

IMAC Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BACK vs FCHS, NHLG, NIVF: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMAC Holdings Margin of Safety % (DCF Earnings Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's Margin of Safety % (DCF Earnings Based) falls into.


IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.